YAP/TAZ at the Roots of Cancer.

YAP and TAZ are highly related transcriptional regulators pervasively activated in human malignancies. Recent work indicates that, remarkably, YAP/TAZ are essential for cancer initiation or growth of most solid tumors. Their activation induces cancer stem cell attributes, proliferation, chemoresistance, and metastasis. YAP/TAZ are sensors of the structural and mechanical features of the cell microenvironment. A number of cancer-associated extrinsic and intrinsic cues conspire to overrule the YAP-inhibiting microenvironment of normal tissues, including changes in mechanotransduction, inflammation, oncogenic signaling, and regulation of the Hippo pathway. Addiction to YAP/TAZ thus potentially represents a central cancer vulnerability that may be exploited therapeutically.

[1]  S. Bicciato,et al.  YAP enhances the pro‐proliferative transcriptional activity of mutant p53 proteins , 2016, EMBO reports.

[2]  C. Eberhart,et al.  Yes-Associated Protein 1 Is Widely Expressed in Human Brain Tumors and Promotes Glioblastoma Growth , 2011, Journal of neuropathology and experimental neurology.

[3]  M. Yaffe,et al.  Canonical Wnt signalling activates TAZ through PP1A during osteogenic differentiation , 2014, Cell Death and Differentiation.

[4]  D. Haber,et al.  salvador Promotes Both Cell Cycle Exit and Apoptosis in Drosophila and Is Mutated in Human Cancer Cell Lines , 2002, Cell.

[5]  F. Zhou,et al.  Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder , 2013, BMC Cancer.

[6]  B. Pruitt,et al.  Mechanical strain induces E-cadherin–dependent Yap1 and β-catenin activation to drive cell cycle entry , 2015, Science.

[7]  D. Moore,et al.  Bile acids activate YAP to promote liver carcinogenesis. , 2013, Cell reports.

[8]  Zhaoming Li,et al.  TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells. , 2015, Biochemical and biophysical research communications.

[9]  Caroline H. Diep,et al.  Down-Regulation of Yes Associated Protein 1 Expression Reduces Cell Proliferation and Clonogenicity of Pancreatic Cancer Cells , 2012, PloS one.

[10]  D. Tuveson,et al.  SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. , 2011, The Journal of clinical investigation.

[11]  Young Chul Kim,et al.  Alternative Wnt Signaling Activates YAP/TAZ , 2015, Cell.

[12]  Gi Jeong Kim,et al.  Increased Expression of Yes-Associated Protein 1 in Hepatocellular Carcinoma with Stemness and Combined Hepatocellular-Cholangiocarcinoma , 2013, PloS one.

[13]  M. Yaffe,et al.  TAZ: a novel transcriptional co‐activator regulated by interactions with 14‐3‐3 and PDZ domain proteins , 2000, The EMBO journal.

[14]  Q. Pan,et al.  Mutual interaction between YAP and c-Myc is critical for carcinogenesis in liver cancer. , 2013, Biochemical and biophysical research communications.

[15]  J. Wrana,et al.  Yap-dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and cancer , 2015, Nature.

[16]  G. M. Rudakova,et al.  α-Catenin Is a Tumor Suppressor That Controls Cell Accumulation by Regulating the Localization and Activity of the Transcriptional Coactivator Yap1 , 2011, Science Signaling.

[17]  Z. Xuan,et al.  Deregulation of Scribble Promotes Mammary Tumorigenesis and Reveals a Role for Cell Polarity in Carcinoma , 2008, Cell.

[18]  I. Hariharan,et al.  The Drosophila Mst Ortholog, hippo, Restricts Growth and Cell Proliferation and Promotes Apoptosis , 2003, Cell.

[19]  H. Ohgaki,et al.  Alterations in the NF2/LATS1/LATS2/YAP Pathway in Schwannomas , 2015, Journal of neuropathology and experimental neurology.

[20]  Joseph Rosenbluh,et al.  KRAS and YAP1 Converge to Regulate EMT and Tumor Survival , 2014, Cell.

[21]  F. Camargo,et al.  Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance , 2011, Proceedings of the National Academy of Sciences.

[22]  A. Asthagiri,et al.  Matrix stiffening sensitizes epithelial cells to EGF and enables the loss of contact inhibition of proliferation , 2011, Journal of Cell Science.

[23]  S. Bicciato,et al.  The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.

[24]  M. Giovannini,et al.  Tumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap/Taz transcriptional coactivators , 2013, Development.

[25]  G. Mills,et al.  Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. , 2014, Anticancer research.

[26]  S. Aerts,et al.  Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state , 2015, Nature Communications.

[27]  M. Biffoni,et al.  TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells , 2014, Oncogene.

[28]  Valerie M. Weaver,et al.  A tense situation: forcing tumour progression , 2009, Nature Reviews Cancer.

[29]  H. Ji,et al.  YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin. , 2015, Cancer research.

[30]  A. Wellstein,et al.  Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma , 2014, Science Signaling.

[31]  Y. Ip,et al.  The conserved misshapen-warts-Yorkie pathway acts in enteroblasts to regulate intestinal stem cells in Drosophila. , 2014, Developmental cell.

[32]  J. Palacios,et al.  Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. , 2015, Endocrine-related cancer.

[33]  D. McCollum,et al.  Angiomotins link F-actin architecture to Hippo pathway signaling , 2014, Molecular biology of the cell.

[34]  B. Thompson,et al.  The Hippo pathway polarizes the actin cytoskeleton during collective migration of Drosophila border cells , 2013, The Journal of cell biology.

[35]  Thomas D. Wu,et al.  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016, Nature Genetics.

[36]  Randy L. Johnson,et al.  Hippo Pathway Inhibits Wnt Signaling to Restrain Cardiomyocyte Proliferation and Heart Size , 2011, Science.

[37]  Patrick Cahan,et al.  Hippo Pathway Activity Influences Liver Cell Fate , 2014, Cell.

[38]  Sharon Gerecht,et al.  Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis , 2015, Proceedings of the National Academy of Sciences.

[39]  Q. Wang,et al.  TAZ promotes epithelial to mesenchymal transition via the upregulation of connective tissue growth factor expression in neuroblastoma cells , 2014, Molecular medicine reports.

[40]  J. Inazawa,et al.  YAP is a candidate oncogene for esophageal squamous cell carcinoma. , 2011, Carcinogenesis.

[41]  H. Ji,et al.  VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex , 2014, Cell Research.

[42]  Lei Zhang,et al.  Hippo signaling regulates Yorkie nuclear localization and activity through 14-3-3 dependent and independent mechanisms. , 2010, Developmental biology.

[43]  M. Giovannini,et al.  NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. , 2003, Genes & development.

[44]  U. Apte,et al.  Deregulation of Hippo kinase signalling in Human hepatic malignancies , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[45]  T. Xu,et al.  Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. , 1995, Development.

[46]  Wen-Bin Li,et al.  YAP is closely correlated with castration-resistant prostate cancer, and downregulation of YAP reduces proliferation and induces apoptosis of PC-3 cells , 2015, Molecular medicine reports.

[47]  Yan Wang,et al.  Clinical and prognostic significance of Yes-associated protein in colorectal cancer , 2013, Tumor Biology.

[48]  Melinda M. Mulvihill,et al.  Ski regulates Hippo and TAZ signaling to suppress breast cancer progression , 2015, Science Signaling.

[49]  D. Pan,et al.  The hippo signaling pathway in development and cancer. , 2010, Developmental cell.

[50]  Jun Yu,et al.  Yes-Associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates with Poor Prognosis , 2011, Clinical Cancer Research.

[51]  M. Rubin,et al.  Novel YAP1‐TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma , 2013, Genes, chromosomes & cancer.

[52]  Shian Wu,et al.  hippo Encodes a Ste-20 Family Protein Kinase that Restricts Cell Proliferation and Promotes Apoptosis in Conjunction with salvador and warts , 2003, Cell.

[53]  Jie Pan,et al.  Lentivirus-mediated RNA interference targeting WWTR1 in human colorectal cancer cells inhibits cell proliferation in vitro and tumor growth in vivo. , 2012, Oncology reports.

[54]  Andrew J Ewald,et al.  A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis , 2014, Genes & development.

[55]  Songshu Meng,et al.  YAP Enhances Autophagic Flux to Promote Breast Cancer Cell Survival in Response to Nutrient Deprivation , 2015, PloS one.

[56]  W. Xiao,et al.  Expression of Yes-associated protein in non-small cell lung cancer and its relationship with clinical pathological factors. , 2012, Chinese medical journal.

[57]  May Yin Lee,et al.  Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity , 2015, Nature.

[58]  Han-Sung Jung,et al.  YAP and TAZ regulate skin wound healing. , 2014, The Journal of investigative dermatology.

[59]  P J Bryant,et al.  The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. , 1995, Genes & development.

[60]  G. Halder,et al.  Modulating F‐actin organization induces organ growth by affecting the Hippo pathway , 2011, The EMBO journal.

[61]  R. Virchow,et al.  Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre , 1861 .

[62]  Pedro Gaspar,et al.  Actin-Capping Protein and the Hippo pathway regulate F-actin and tissue growth in Drosophila , 2011, Development.

[63]  N. Tapon,et al.  Differential control of Yorkie activity by LKB1/AMPK and the Hippo/Warts cascade in the central nervous system , 2015, Proceedings of the National Academy of Sciences.

[64]  R. Hynes,et al.  The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain , 2012, Proceedings of the National Academy of Sciences.

[65]  S. Dedhar,et al.  Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase , 2013, Nature Communications.

[66]  D. Calvisi,et al.  The Hippo–Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis , 2010, Proceedings of the National Academy of Sciences.

[67]  Kwok-Kin Wong,et al.  A genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway , 2013, Nature Cell Biology.

[68]  S. Sheen-Chen,et al.  Yes-associated protein is not an independent prognostic marker in breast cancer. , 2012, Anticancer research.

[69]  G. Lou,et al.  Clinical Significance of Yes-Associated Protein Overexpression in Cervical Carcinoma: The Differential Effects Based on Histotypes , 2013, International Journal of Gynecologic Cancer.

[70]  P. Northcott,et al.  Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation , 2011, Oncogene.

[71]  Jun O. Liu,et al.  Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. , 2012, Genes & development.

[72]  E. Oki,et al.  An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression. , 2015, Cancer research.

[73]  Jill P. Mesirov,et al.  β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis , 2012, Cell.

[74]  Arie Perry,et al.  Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups , 2011, Acta Neuropathologica.

[75]  Jianbin Huang,et al.  The Hippo Signaling Pathway Coordinately Regulates Cell Proliferation and Apoptosis by Inactivating Yorkie, the Drosophila Homolog of YAP , 2005, Cell.

[76]  Jing Zhao,et al.  Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions. , 2009, World journal of gastroenterology.

[77]  J. George,et al.  The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene , 2011, Oncogene.

[78]  Randy L. Johnson,et al.  AMPK modulates Hippo pathway activity to regulate energy homeostasis , 2015, Nature Cell Biology.

[79]  Stefano Monti,et al.  A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma , 2015, Molecular Cancer Research.

[80]  C. Antonescu,et al.  A novel WWTR1‐CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites , 2011, Genes, chromosomes & cancer.

[81]  S. Dupont,et al.  The biology of YAP/TAZ: hippo signaling and beyond. , 2014, Physiological reviews.

[82]  Fei Li,et al.  The YAP1 oncogene contributes to bladder cancer cell proliferation and migration by regulating the H19 long noncoding RNA. , 2015, Urologic oncology.

[83]  L. Zhu,et al.  Tead and AP1 Coordinate Transcription and Motility. , 2016, Cell reports.

[84]  Shan Jiang,et al.  Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer , 2014, Cell.

[85]  P. Northcott,et al.  YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. , 2009, Genes & development.

[86]  R. Rosell,et al.  TAZ Is Highly Expressed in Gastric Signet Ring Cell Carcinoma , 2014, BioMed research international.

[87]  N. Carragher,et al.  ADF and Cofilin1 Control Actin Stress Fibers, Nuclear Integrity, and Cell Survival , 2015, Cell reports.

[88]  Bo Li,et al.  The Role and Clinical Significance of Yes-Associated Protein 1 in Human Osteosarcoma , 2013, International journal of immunopathology and pharmacology.

[89]  Li-juan Wang,et al.  Expression and Clinical Significance of YAP, TAZ, and AREG in Hepatocellular Carcinoma , 2014, Journal of immunology research.

[90]  Antonio Marchetti,et al.  The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies , 2015, Nature Genetics.

[91]  Kang Zhang,et al.  Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. , 2014, Cancer cell.

[92]  Jindan Yu,et al.  Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. , 2012, Genes & development.

[93]  W. Hong,et al.  TEADs Mediate Nuclear Retention of TAZ to Promote Oncogenic Transformation* , 2009, Journal of Biological Chemistry.

[94]  T. Okano,et al.  Hippo pathway regulation by cell morphology and stress fibers , 2011, Development.

[95]  J. Llovet,et al.  YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. , 2015, Cell reports.

[96]  Xiang-Dong Fu,et al.  Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling , 2012, Cell.

[97]  M. Tsao,et al.  TAZ is a novel oncogene in non-small cell lung cancer , 2011, Oncogene.

[98]  E. Wagner,et al.  Chronic inflammation imposes aberrant cell fate in regenerating epithelia through mechanotransduction , 2015, Nature Cell Biology.

[99]  Hoguen Kim,et al.  Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer. , 2012, Anticancer research.

[100]  T. Pawson,et al.  Yap- and Cdc42-Dependent Nephrogenesis and Morphogenesis during Mouse Kidney Development , 2013, PLoS genetics.

[101]  J. Reis-Filho,et al.  Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein , 2016, Oncogene.

[102]  Ganesh Rao,et al.  The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. , 2011, Genes & development.

[103]  Daniel T. Montoro,et al.  Tumor‐propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis , 2014, The EMBO journal.

[104]  W. Jung,et al.  Expression of Yes-associated protein (YAP) in metastatic breast cancer. , 2015, International journal of clinical and experimental pathology.

[105]  A. Borczuk,et al.  Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells , 2015, Oncotarget.

[106]  H. Fan,et al.  YAP Promotes Ovarian Cancer Cell Tumorigenesis and Is Indicative of a Poor Prognosis for Ovarian Cancer Patients , 2014, PloS one.

[107]  N. Tapon,et al.  Sensing the local environment: actin architecture and Hippo signalling. , 2014, Current opinion in cell biology.

[108]  J. Ajani,et al.  The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer , 2015, Clinical Cancer Research.

[109]  William C Hines,et al.  Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression , 2011, Nature Medicine.

[110]  N. Sarvetnick,et al.  Hippo Signaling Regulates Pancreas Development through Inactivation of Yap , 2012, Molecular and Cellular Biology.

[111]  K. Guan,et al.  Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway , 2014, Oncogene.

[112]  John T. Chang,et al.  A gp130–Src–YAP module links inflammation to epithelial regeneration , 2015, Nature.

[113]  Boon Chuan Low,et al.  YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth , 2014, FEBS letters.

[114]  Nicola Elvassore,et al.  Role of YAP/TAZ in mechanotransduction , 2011, Nature.

[115]  Jing Zhao,et al.  Overexpression of YAP1 is Correlated with Progression, Metastasis and Poor Prognosis in Patients with Gastric Carcinoma , 2014, Pathology & Oncology Research.

[116]  S. Piccolo,et al.  Eradicating tumor drug resistance at its YAP‐biomechanical roots , 2016, The EMBO journal.

[117]  Hans Clevers,et al.  Wnt/β-Catenin Signaling in Development and Disease , 2006, Cell.

[118]  D. Calvisi,et al.  Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. , 2014, Gastroenterology.

[119]  R. Drapkin,et al.  YAP Induces High-Grade Serous Carcinoma in Fallopian Tube Secretory Epithelial Cells , 2015, Oncogene.

[120]  R. M. Simpson,et al.  Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression , 2010, Proceedings of the National Academy of Sciences.

[121]  M. Roncalli,et al.  YAP activation is an early event and a potential therapeutic target in liver cancer development. , 2014, Journal of hepatology.

[122]  Jianmin Zhang,et al.  YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage , 2015, Oncogene.

[123]  Shian Wu,et al.  The Hippo effector Yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression. , 2013, Developmental cell.

[124]  Jindan Yu,et al.  A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis , 2015, Cell Research.

[125]  G. Riggins,et al.  Yes-Associated Protein 1 Is Activated and Functions as an Oncogene in Meningiomas , 2012, Molecular Cancer Research.

[126]  Jongshin Kim,et al.  Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation , 2016, The EMBO journal.

[127]  Y. Sekido,et al.  Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness , 2015, Journal of neuropathology and experimental neurology.

[128]  M. Sudol,et al.  Yes-Associated Protein (YAP) Modulates Oncogenic Features and Radiation Sensitivity in Endometrial Cancer , 2014, PloS one.

[129]  M. Wigler,et al.  Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach , 2006, Cell.

[130]  Peijing Zhang,et al.  LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker , 2012, Nature Medicine.

[131]  H. Ji,et al.  A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. , 2014, Cancer cell.

[132]  P. Nelson,et al.  ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors. , 2015, Cancer cell.

[133]  Nora C. Toussaint,et al.  In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survival , 2014, Pigment Cell & Melanoma Research.

[134]  Q. Zeng,et al.  A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. , 2008, Cancer research.

[135]  L. Chin,et al.  Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. , 2016, Cancer discovery.

[136]  E. Nishida,et al.  A molecular mechanism that links Hippo signalling to the inhibition of Wnt/β‐catenin signalling , 2012, The EMBO journal.

[137]  Kun-Liang Guan,et al.  Mechanisms of Hippo pathway regulation , 2016, Genes & development.

[138]  R. Maria,et al.  The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy , 2014, Oncotarget.

[139]  G. Halder,et al.  MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway , 2015, Nature Communications.

[140]  G. Tonon,et al.  RESCUE OF HIPPO CO-ACTIVATOR YAP1 TRIGGERS DNA DAMAGE-INDUCED APOPTOSIS IN HEMATOLOGICAL CANCERS , 2014, Nature Medicine.

[141]  M. Perez-Moreno,et al.  Epithelial cell polarity, stem cells and cancer , 2011, Nature Reviews Cancer.

[142]  Lin Mei,et al.  Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility , 2013, Proceedings of the National Academy of Sciences.

[143]  Xiaoqian Zhang,et al.  TAZ Expression as a Prognostic Indicator in Colorectal Cancer , 2013, PloS one.

[144]  M. Giovannini,et al.  The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. , 2010, Developmental cell.

[145]  Yoshimitsu Abiko,et al.  An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non–Small Cell Lung Cancer , 2014, Clinical Cancer Research.

[146]  K. Song,et al.  Differential expression of Yes-associated protein and phosphorylated Yes-associated protein is correlated with expression of Ki-67 and phospho-ERK in colorectal adenocarcinoma. , 2013, Histology and histopathology.

[147]  A. Maitra,et al.  The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. , 2010, Genes & development.

[148]  W. Jung,et al.  Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer. , 2014, International journal of clinical and experimental pathology.

[149]  H. Nojima,et al.  Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP , 2015, Genes & development.

[150]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[151]  G. Feldmann,et al.  Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals , 2007, Cell.

[152]  Ju-Seog Lee,et al.  Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver , 2010, Proceedings of the National Academy of Sciences.

[153]  M. Herlyn,et al.  Pro-Invasive Activity of the Hippo Pathway Effectors YAP and TAZ in Cutaneous Melanoma , 2013, The Journal of investigative dermatology.

[154]  Li-juan Wang,et al.  Overexpression of YAP and TAZ Is an Independent Predictor of Prognosis in Colorectal Cancer and Related to the Proliferation and Metastasis of Colon Cancer Cells , 2013, PloS one.

[155]  L. Yao,et al.  Functional and Clinical Evidence That TAZ is a Candidate Oncogene in Hepatocellular Carcinoma , 2015, Journal of cellular biochemistry.

[156]  Yonggang Zheng,et al.  Spatial Organization of Hippo Signaling at the Plasma Membrane Mediated by the Tumor Suppressor Merlin/NF2 , 2013, Cell.

[157]  Q. Ou,et al.  Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. , 2012, European journal of cancer.

[158]  Jie Cheng,et al.  The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer , 2015, Molecular oncology.

[159]  R. Jaenisch,et al.  YAP1 Increases Organ Size and Expands Undifferentiated Progenitor Cells , 2007, Current Biology.

[160]  S. Seshagiri,et al.  The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer , 2013, Nature Reviews Cancer.

[161]  Qiang Liu,et al.  TAZ regulates cell proliferation and epithelial–mesenchymal transition of human hepatocellular carcinoma , 2015, Cancer science.

[162]  S. Bicciato,et al.  Aerobic glycolysis tunes YAP/TAZ transcriptional activity , 2015, The EMBO journal.

[163]  P. Singh,et al.  Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3 , 2015, Oncotarget.

[164]  Seon-Young Kim,et al.  A basal-like breast cancer-specific role for SRF–IL6 in YAP-induced cancer stemness , 2015, Nature Communications.

[165]  G. G. Galli,et al.  The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. , 2014, Cancer cell.

[166]  K. Song,et al.  Correlation of expression of phosphorylated and non-phosphorylated Yes-associated protein with clinicopathological parameters in esophageal squamous cell carcinoma in a Korean population. , 2012, Anticancer research.

[167]  D. Tomchick,et al.  Structural and functional analysis of the YAP-binding domain of human TEAD2 , 2010, Proceedings of the National Academy of Sciences.

[168]  X. Matías-Guiu,et al.  A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer , 2015, Modern Pathology.

[169]  Piyush B. Gupta,et al.  The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. , 2014, Cell reports.

[170]  S. Hilsenbeck,et al.  Hippo pathway effector Yap is an ovarian cancer oncogene. , 2010, Cancer research.

[171]  M. Sudol,et al.  Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. , 1994, Oncogene.

[172]  P. Yuan,et al.  Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression , 2014, Oncogene.

[173]  S. Bicciato,et al.  Role of TAZ as Mediator of Wnt Signaling , 2012, Cell.

[174]  K. Guan,et al.  Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway , 2015, Nature Cell Biology.

[175]  Robert P. Jenkins,et al.  Mechano-transduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer associated fibroblasts , 2013, Nature Cell Biology.

[176]  A. Rosato,et al.  Metabolic control of YAP and TAZ by the mevalonate pathway , 2014, Nature Cell Biology.

[177]  Ju-Seog Lee,et al.  Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients , 2014, Clinical Cancer Research.

[178]  Antonio Rosato,et al.  Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth , 2015, Nature Cell Biology.

[179]  Gang Liang,et al.  Expression of Yes-Associated Protein in Cervical Squamous Epithelium Lesions , 2014, International Journal of Gynecologic Cancer.

[180]  Hidemi Ito,et al.  TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth , 2012, The Journal of experimental medicine.

[181]  C. Mein,et al.  Yes-associated protein (YAP) functions as a tumor suppressor in breast , 2008, Cell Death and Differentiation.

[182]  Jeannie T. Lee,et al.  Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. , 2009, Cancer cell.

[183]  G. Merlino,et al.  Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. , 2014, Cancer cell.

[184]  Clare M. Waterman,et al.  YAP Nuclear Localization in the Absence of Cell-Cell Contact Is Mediated by a Filamentous Actin-dependent, Myosin II- and Phospho-YAP-independent Pathway during Extracellular Matrix Mechanosensing* , 2016, The Journal of Biological Chemistry.

[185]  S. Lowe,et al.  Yes‐associated protein is an independent prognostic marker in hepatocellular carcinoma , 2009, Cancer.

[186]  W. Hong,et al.  Structural basis of YAP recognition by TEAD4 in the hippo pathway. , 2010, Genes & development.

[187]  Y. Kondo,et al.  LATS2 is a tumor suppressor gene of malignant mesothelioma. , 2011, Cancer research.

[188]  D. Placantonakis,et al.  Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells , 2015, Nature Communications.

[189]  Nicholas Y. Palermo,et al.  The Hippo Pathway Effector YAP Regulates Motility, Invasion, and Castration-Resistant Growth of Prostate Cancer Cells , 2015, Molecular and Cellular Biology.

[190]  I. Clay,et al.  YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers , 2015, PLoS genetics.

[191]  A. Maitra,et al.  β-Catenin destruction complex-independent regulation of Hippo–YAP signaling by APC in intestinal tumorigenesis , 2015, Genes & development.

[192]  David M. Thomas,et al.  The Hippo pathway and human cancer , 2013, Nature Reviews Cancer.

[193]  P. Hupé,et al.  Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas. , 2014, Neuro-oncology.

[194]  P. Lambert,et al.  The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression , 2015, EMBO molecular medicine.

[195]  J. Ajani,et al.  Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. , 2014, Cancer research.

[196]  S. Lowe,et al.  AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma , 2011, Oncogene.

[197]  P. Chuang,et al.  A conserved MST1/2-YAP axis mediates Hippo signaling during lung growth. , 2015, Developmental biology.

[198]  Daniel G. Anderson,et al.  Loss of α-catenin elicits a cholestatic response and impairs liver regeneration , 2014, Scientific Reports.

[199]  O. Kirak,et al.  Yap1 Acts Downstream of α-Catenin to Control Epidermal Proliferation , 2011, Cell.

[200]  M. Greene,et al.  Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis , 2015, Scientific Reports.

[201]  S. Vandenberg,et al.  The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. , 2008, Neoplasia.

[202]  Hongyun Zhao,et al.  Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[203]  Hang He,et al.  Two-signal requirement for growth-promoting function of Yap in hepatocytes , 2015, eLife.

[204]  E. Wang,et al.  Overexpression of yes‐associated protein contributes to progression and poor prognosis of non‐small‐cell lung cancer , 2010, Cancer science.

[205]  E. Ballestar,et al.  Autophagy maintains stemness by preventing senescence , 2016, Nature.

[206]  Jiandie D. Lin,et al.  TEAD mediates YAP-dependent gene induction and growth control. , 2008, Genes & development.

[207]  S. Arron,et al.  αE-catenin inhibits a Src–YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway , 2016, Genes & development.

[208]  N. Elvassore,et al.  A Mechanical Checkpoint Controls Multicellular Growth through YAP/TAZ Regulation by Actin-Processing Factors , 2013, Cell.

[209]  Xiao Han,et al.  Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy. , 2015, Structure.

[210]  Nam‐Gyun Kim,et al.  E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components , 2011, Proceedings of the National Academy of Sciences.

[211]  Li Li,et al.  Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. , 2007, Genes & development.

[212]  Valerie M. Weaver,et al.  Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors , 2015, Molecular biology of the cell.

[213]  F. van Roy,et al.  Alpha-Catenins Control Cardiomyocyte Proliferation by Regulating Yap Activity , 2015, Circulation research.

[214]  B. Mao,et al.  SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma , 2014, Oncogene.

[215]  Erik Sahai,et al.  Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling , 2015, Cancer cell.

[216]  E. Olson,et al.  Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex , 2014, The Journal of experimental medicine.

[217]  N. Yang,et al.  Characterization of TAZ domains important for the induction of breast cancer stem cell properties and tumorigenesis , 2015, Cell cycle.

[218]  J. Asara,et al.  Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. , 2014, Cell reports.

[219]  Toby C. Cornish,et al.  Yes-Associated Protein Regulates the Hepatic Response After Bile Duct Ligation , 2012, Hepatology.

[220]  G. G. Galli,et al.  YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers. , 2015, Molecular cell.

[221]  Stefano Piccolo,et al.  Transduction of mechanical and cytoskeletal cues by YAP and TAZ , 2012, Nature Reviews Molecular Cell Biology.

[222]  E. Fuchs,et al.  Plasticity of epithelial stem cells in tissue regeneration , 2014, Science.

[223]  Shuji Ogino,et al.  Restriction of intestinal stem cell expansion and the regenerative response by YAP , 2012, Nature.

[224]  Giuseppe Basso,et al.  YAP/TAZ Incorporation in the β-Catenin Destruction Complex Orchestrates the Wnt Response , 2014, Cell.